GILD supply chain intelligence for Gilead Sciences, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Gilead Sciences, Inc. (GILD) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| IOCB | IOCB | 90% | License Agreement, dated December 15, 1991, between Registrant, IOCB and REGA |
| REGA | REGA | 90% | License Agreement, dated December 15, 1991, between Registrant, IOCB and REGA |
| CGEN | Compugen Ltd. | 85% | Reciprocal relationship from CGEN graph: below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates. F - 2 Kost Forer Gabbay & Kasierer 144… |
| EMORY-UNIVERSITY | EMORY-UNIVERSITY | 85% | Exclusive License Agreement by and between Registrant (as successor to Triangle Pharmaceuticals, Inc.), Glaxo Group Limited, The Wellcome Foundation Limited, Glaxo Wellcome Inc. and Emory University,… |
| GLAXO-GROUP-LIMITED | GLAXO-GROUP-LIMITED | 85% | Exclusive License Agreement by and between Registrant (as successor to Triangle Pharmaceuticals, Inc.), Glaxo Group Limited, The Wellcome Foundation Limited, Glaxo Wellcome Inc. and Emory University,… |
| GLAXO-WELLCOME-INC | GLAXO-WELLCOME-INC | 85% | Exclusive License Agreement by and between Registrant (as successor to Triangle Pharmaceuticals, Inc.), Glaxo Group Limited, The Wellcome Foundation Limited, Glaxo Wellcome Inc. and Emory University,… |
| THE-WELLCOME-FOUNDATION-LIMITED | THE-WELLCOME-FOUNDATION-LIMITED | 85% | Exclusive License Agreement by and between Registrant (as successor to Triangle Pharmaceuticals, Inc.), Glaxo Group Limited, The Wellcome Foundation Limited, Glaxo Wellcome Inc. and Emory University,… |
| AGEN | Agenus Inc. | 72% | Reciprocal relationship from AGEN graph: Reciprocal relationship from GILD graph: Reciprocal relationship from AGEN graph: — 2,057 Total $ 20,362 $ ( 17,325 ) $ 3,037 The weighted average amortizatio… |
| ASMB | Assembly Biosciences, Inc. | 72% | Reciprocal relationship from ASMB graph: Reciprocal relationship from GILD graph: Reciprocal relationship from ASMB graph: nd ABI-1179 (1179); (2) an orally bioavailable hepatitis delta virus (HDV) e… |
| AVIR | Atea Pharmaceuticals, Inc. | 72% | Reciprocal relationship from AVIR graph: Reciprocal relationship from GILD graph: Reciprocal relationship from AVIR graph: Reciprocal relationship from GILD graph: Reciprocal relationship from AVIR g… |
| CABA | Cabaletta Bio, Inc. | 72% | Reciprocal relationship from CABA graph: ticipated in the forward-looking statements as a result of factors that are described below and elsewhere in this Quarterly Report. The risk factors denoted w… |
| CAH | Cardinal Health, Inc. | 72% | Reciprocal relationship from CAH graph: Reciprocal relationship from GILD graph: erns of our non-retail customers. In light of the budget crises faced by many European countries, we have observed var… |
| CAH | Cardinal Health, Inc. | 72% | erns of our non-retail customers. In light of the budget crises faced by many European countries, we have observed variations in purchasing patterns induced by cost containment measures in Europe. We… |
| CBIH | Cannabis Bioscience International Holdings, Inc. | 72% | Reciprocal relationship from CBIH graph: Reciprocal relationship from GILD graph: Reciprocal relationship from CBIH graph: Reciprocal relationship from GILD graph: Reciprocal relationship from CBIH g… |
| CEROW | CEROW | 72% | Reciprocal relationship from CEROW graph: Reciprocal relationship from GILD graph: Reciprocal relationship from CEROW graph: y engineered T cells. Adoptively transferred T cells proliferate upon thei… |
| CHRS | Coherus Oncology, Inc. | 72% | Reciprocal relationship from CHRS graph: Reciprocal relationship from GILD graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from GILD graph: Reciprocal relationship from CHRS g… |
| CRIS | Curis, Inc. | 72% | Reciprocal relationship from CRIS graph: to the processing of personal data that takes place in the UK and includes parallel obligations to those set forth by GDPR. In relation to data transfers, bot… |
| CRM | Salesforce, Inc. | 72% | Reciprocal relationship from CRM graph: en & Katz, where he practiced law from September 2006 to July 2023. Mr. Niles received his B.S., B.A. and B.S. in Finance, Economics and Decision & Information… |
| GDTC | CytoMed Therapeutics Limited | 72% | Reciprocal relationship from GDTC graph: l expansion. ATPL retained the right to use all products and/or services the Company creates which contain or incorporate the modified human K562 cells. Any n… |
| GLAXF | GSK plc | 72% | Reciprocal relationship from GLAXF graph: rporate and other unallocated impairment reversals ( 3 ) ( 14 ) – Other reconciling items between segment impairment reversals and total impairment reversals… |
| GLMD | Galmed Pharmaceuticals Ltd. | 72% | Reciprocal relationship from GLMD graph: Reciprocal relationship from GILD graph: Reciprocal relationship from GLMD graph: Reciprocal relationship from GILD graph: Reciprocal relationship from GLMD g… |
| GLPG | Lakefront Biotherapeutics NV | 72% | Reciprocal relationship from GLPG graph: Reciprocal relationship from GILD graph: Reciprocal relationship from GLPG graph: Reciprocal relationship from GILD graph: Reciprocal relationship from GLPG g… |
| IBIO | iBio, Inc. | 72% | Reciprocal relationship from IBIO graph: icantly more experience commercializing drugs that have been approved for marketing. Mergers and acquisitions in the pharmaceutical and biotechnology industri… |
| KDOZF | Kidoz Inc. | 72% | Reciprocal relationship from KDOZF graph: Reciprocal relationship from GILD graph: Reciprocal relationship from KDOZF graph: Reciprocal relationship from GILD graph: Reciprocal relationship from KDOZ… |
| KYMR | Kymera Therapeutics, Inc. | 72% | Reciprocal relationship from KYMR graph: Reciprocal relationship from GILD graph: Reciprocal relationship from KYMR graph: nties associated with product development, we are unable to predict the timi… |
| KYTX | Kyverna Therapeutics, Inc. | 72% | Reciprocal relationship from KYTX graph: Reciprocal relationship from GILD graph: Reciprocal relationship from KYTX graph: ase 1 data from both of these trials in the second half of 2025. In November… |
| MCK | McKesson Corporation | 72% | Reciprocal relationship from MCK graph: Reciprocal relationship from GILD graph: erns of our non-retail customers. In light of the budget crises faced by many European countries, we have observed var… |
| MCK | McKesson Corporation | 72% | erns of our non-retail customers. In light of the budget crises faced by many European countries, we have observed variations in purchasing patterns induced by cost containment measures in Europe. We… |
| MGNX | MacroGenics, Inc. | 72% | Reciprocal relationship from MGNX graph: Reciprocal relationship from GILD graph: Reciprocal relationship from MGNX graph: Reciprocal relationship from GILD graph: Reciprocal relationship from MGNX g… |
| NRIX | Nurix Therapeutics, Inc. | 72% | Reciprocal relationship from NRIX graph: Reciprocal relationship from GILD graph: Reciprocal relationship from NRIX graph: Reciprocal relationship from GILD graph: Reciprocal relationship from NRIX g… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CAH | Cardinal Health, Inc. | 85% | Reciprocal relationship from CAH graph: Reciprocal relationship from GILD graph: Reciprocal relationship from CAH graph: Reciprocal relationship from GILD graph: Reciprocal relationship from CAH grap… |
| CAH | Cardinal Health, Inc. | 85% | erns of our non-retail customers. In light of the budget crises faced by many European countries, we have observed variations in purchasing patterns induced by cost containment measures in Europe. We… |
| CARDINAL-HEALTH-INC-CENCORA-INC | CARDINAL-HEALTH-INC-CENCORA-INC | 85% | atterns of our non-retail customers. In light of the budget crises faced by many European countries, we have observed variations in purchasing patterns induced by cost containment measures in Europe.… |
| MCK | McKesson Corporation | 85% | erns of our non-retail customers. In light of the budget crises faced by many European countries, we have observed variations in purchasing patterns induced by cost containment measures in Europe. We… |
| MCK | McKesson Corporation | 85% | Reciprocal relationship from MCK graph: Reciprocal relationship from GILD graph: Reciprocal relationship from MCK graph: Reciprocal relationship from GILD graph: erns of our non-retail customers. In … |
| ASMB | Assembly Biosciences, Inc. | 72% | 48 434 238 116 47 401 8 % Total HIV 15,918 2,339 1,355 19,612 14,848 2,102 1,226 18,175 8 % Liver Disease Sofosbuvir/Velpatasvir (3) 922 299 374 1,596 859 323 355 1,537 4 % Vemlidy 486 44 428 959 410… |
| ASMB | Assembly Biosciences, Inc. | 72% | Reciprocal relationship from ASMB graph: Reciprocal relationship from GILD graph: 48 434 238 116 47 401 8 % Total HIV 15,918 2,339 1,355 19,612 14,848 2,102 1,226 18,175 8 % Liver Disease Sofosbuvir/… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from GILD graph: O Pharma will hold exclusive global rights to STAT6 topical formulations in dermatology. Upon closing of the agreement… |
| BMY | Bristol-Myers Squibb Company | 72% | O Pharma will hold exclusive global rights to STAT6 topical formulations in dermatology. Upon closing of the agreement, we made a $ 250 million upfront payment to LEO Pharma. In addition, LEO Pharma … |
| BMYMP | Bristol-Myers Squibb Co | 72% | O Pharma will hold exclusive global rights to STAT6 topical formulations in dermatology. Upon closing of the agreement, we made a $ 250 million upfront payment to LEO Pharma. In addition, LEO Pharma … |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from GILD graph: O Pharma will hold exclusive global rights to STAT6 topical formulations in dermatology. Upon closing of the agreeme… |
| CHRS | Coherus Oncology, Inc. | 72% | Reciprocal relationship from CHRS graph: plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimburs… |
| GDTC | CytoMed Therapeutics Limited | 72% | Reciprocal relationship from GDTC graph: Reciprocal relationship from GILD graph: Reciprocal relationship from GDTC graph: Reciprocal relationship from GILD graph: Reciprocal relationship from GDTC g… |
| GLMD | Galmed Pharmaceuticals Ltd. | 72% | Reciprocal relationship from GLMD graph: , contract manufacturers must obtain regulatory approval of their manufacturing facilities, processes and quality systems. In addition, pharmaceutical manufac… |
| GLSI | Greenwich LifeSciences, Inc. | 72% | Reciprocal relationship from GLSI graph: duct candidate and the average exposure time in the clinical development program may be inadequate to detect rare adverse events or chance findings that may o… |
| IBIO | iBio, Inc. | 72% | Reciprocal relationship from IBIO graph: Reciprocal relationship from GILD graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from GILD graph: Reciprocal relationship from IBIO g… |
| IDYA | IDEAYA Biosciences, Inc. | 72% | Reciprocal relationship from IDYA graph: sertib (PKC) Phase 2/3 clinical trials, IDE397 (MAT2A) Phase 1/2 clinical trials, IDE849 (DLL3) Phase 1 clinical trial, IDE161 (PARG) Phase 1/2 clinical trial… |
| INTS | Intensity Therapeutics, Inc. | 72% | Reciprocal relationship from INTS graph: Reciprocal relationship from GILD graph: Reciprocal relationship from INTS graph: n when they do not submit claims directly to government payors if they are d… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from GILD graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from GILD graph: O Pharma will hold exclusive global r… |
| JNJ | Johnson & Johnson | 72% | O Pharma will hold exclusive global rights to STAT6 topical formulations in dermatology. Upon closing of the agreement, we made a $ 250 million upfront payment to LEO Pharma. In addition, LEO Pharma … |
| KYMR | Kymera Therapeutics, Inc. | 72% | Reciprocal relationship from KYMR graph: Reciprocal relationship from GILD graph: Reciprocal relationship from KYMR graph: hese manufacturers on a purchase order basis and do not have long-term suppl… |
| KYTX | Kyverna Therapeutics, Inc. | 72% | Reciprocal relationship from KYTX graph: Reciprocal relationship from GILD graph: Reciprocal relationship from KYTX graph: Reciprocal relationship from GILD graph: Reciprocal relationship from KYTX g… |
| LQDA | Liquidia Corporation | 72% | Reciprocal relationship from LQDA graph: perational fabrication lines are scaled and capable of producing the necessary materials to support our clinical trials and, if approved, initial commercial d… |
| MGNX | MacroGenics, Inc. | 72% | Reciprocal relationship from MGNX graph: lations, which include requirements relating to quality control and quality assurance as well as the corresponding maintenance of records and documentation. F… |
| NRIX | Nurix Therapeutics, Inc. | 72% | Reciprocal relationship from NRIX graph: Reciprocal relationship from GILD graph: Reciprocal relationship from NRIX graph: g Administration (FDA), the European Medicines Agency (EMA) or other regulat… |
| PYXS | Pyxis Oncology, Inc. | 72% | Reciprocal relationship from PYXS graph: Reciprocal relationship from GILD graph: Reciprocal relationship from PYXS graph: Reciprocal relationship from GILD graph: Reciprocal relationship from PYXS g… |
| RCUS | Arcus Biosciences, Inc. | 72% | 48 434 238 116 47 401 8 % Total HIV 15,918 2,339 1,355 19,612 14,848 2,102 1,226 18,175 8 % Liver Disease Sofosbuvir/Velpatasvir (3) 922 299 374 1,596 859 323 355 1,537 4 % Vemlidy 486 44 428 959 410… |
| RCUS | Arcus Biosciences, Inc. | 72% | Reciprocal relationship from RCUS graph: Reciprocal relationship from GILD graph: Reciprocal relationship from RCUS graph: Reciprocal relationship from GILD graph: Reciprocal relationship from RCUS g… |
| RDHL | RedHill Biopharma Ltd. | 72% | Reciprocal relationship from RDHL graph: Reciprocal relationship from GILD graph: Reciprocal relationship from RDHL graph: -content imaging assays, provided further support for activities of Redhill … |
| RNTX | Rein Therapeutics Inc. | 72% | Reciprocal relationship from RNTX graph: Reciprocal relationship from GILD graph: Reciprocal relationship from RNTX graph: Reciprocal relationship from GILD graph: Reciprocal relationship from RNTX g… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| GILD-DEBT | Debt stack $26.2B | 90% | Market cache reports total debt of $26.2B. |
| GILD-DEBT-7255 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2011-12-31. |
| Acquired Entity | Name | Confidence | Evidence |
|---|---|---|---|
| GILD-ACQ-0001104659-26-049874 | Gilead completed the acquisition of Arcellx, Inc. through a tender offer and merger. | 85% | Gilead completed the acquisition of Arcellx, Inc. through a tender offer and merger. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| GILD-OWNER-GILEAD-SCIENCES-INC | GILEAD SCIENCES, INC. | 90% | 13F overlay lists GILEAD SCIENCES, INC. as top holder; 209 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| BNRG | Brenmiller Energy Ltd | 100.00 | 2 | |
| CSTE | Caesarstone Ltd. | 100.00 | 2 | |
| CBIH | Cannabis Bioscience International Holdings, Inc. | 100.00 | 1 | ['supplier'] |
| BNR | Burning Rock Biotech Limited | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| ANIK | Anika Therapeutics, Inc. | 100.00 | 2 | |
| AVIR | Atea Pharmaceuticals, Inc. | 100.00 | 1 | ['supplier'] |
| BEAM | Beam Therapeutics Inc. | 100.00 | 2 | |
| BPTH | Bio-Path Holdings, Inc. | 100.00 | 2 | |
| CLYM | Climb Bio, Inc. | 100.00 | 2 | |
| BLLN | BillionToOne, Inc. | 100.00 | 2 | |
| CCCC | C4 Therapeutics, Inc. | 100.00 | 2 | |
| CEROW | CERO THERAPEUTICS HOLDINGS, INC. | 100.00 | 1 | ['supplier'] |
| AORT | Artivion, Inc. | 100.00 | 2 | |
| AVBP | ArriVent BioPharma, Inc. | 100.00 | 2 | |
| BORAY | Bora Pharmaceuticals Co., Ltd. | 100.00 | 2 | |
| EMMA | Emmaus Life Sciences, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| CLDX | Celldex Therapeutics, Inc. | 100.00 | 2 |